← Leaderboards

M. Javad Aman

University Of California San Diego

Google Scholar ↗PubMed ↗ORCID ↗

$32,287,217

Attributed

$41,919,928

Total exposure

21

Grants

20

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.3M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$41,919,928 · 21

By mechanism

R01$19,874,034 · 5

R44$7,112,941 · 3

U01$5,382,883 · 1

N01$3,445,372 · 1

R43$2,748,164 · 6

R42$1,861,259 · 1

Top collaborators

Others in their field

Top investigators on “Antibodies”

Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
Bambra Strokes · Ppd Development Lp$461,655,950
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
Barton F Haynes · Duke University$372,611,596
Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
Dennis R. Burton · Scripps Research Institute$306,733,901

Research focus

AntibodiesInfectionVaccinesAnimal ModelBaseFutureLeadEpitopesAntigensResponseDesignNonhuman PrimateCellsNeutralizing AntibodyBiological Response Modifier TherapyStaphylococcus AureusPathogenClinical TrialsMonoclonal AntibodiesSuccessCessation Of LifeImmune ResponseToxinSite

Grant awards (58)

Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease$1,000,000

R44 · FY2025 · AI · contact PI

Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control$914,818

R44 · FY2025 · AI · contact PI

Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease$646,138

R01 · FY2025 · AI · contact PI

A multimodal approach for immunotherapy of Staphylococcus aureus bacteremia$638,953

R01 · FY2025 · AI · contact PI

Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control$918,483

R44 · FY2024 · AI · contact PI

Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease$649,379

R01 · FY2024 · AI · contact PI

Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection$619,311

R01 · FY2024 · AI · contact PI

Development of Therapeutic Products for Marburg Virus$1,696,004

N01 · FY2023 · AI · contact PI

Immunotherapy of MRSA Osteomyelitis$1,000,000

R44 · FY2023 · AI · contact PI

Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control$986,248

R44 · FY2023 · AI · contact PI

Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease$670,570

R01 · FY2023 · AI · contact PI

Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection$663,570

R01 · FY2023 · AI · contact PI

Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease$293,392

R44 · FY2023 · AI · contact PI

Immunotherapy of MRSA Osteomyelitis$1,000,000

R44 · FY2022 · AI · contact PI

Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection$727,487

R01 · FY2022 · AI · contact PI

Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease$702,876

R01 · FY2022 · AI · contact PI

Development of Therapeutic Products for Marburg Virus$1,749,368

N01 · FY2021 · AI · contact PI

Immunotherapy of MRSA Osteomyelitis$1,000,000

R44 · FY2021 · AI · contact PI

Rationally Designed Pan-Ebolavirus Vaccine$886,705

R01 · FY2021 · AI · contact PI

Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection$745,628

R01 · FY2021 · AI · contact PI

Evolution of anti-filovirus B cell responses and mechanisms of protection$733,183

R01 · FY2021 · AI · contact PI

Rationally Designed Pan-Ebolavirus Vaccine$166,279

R01 · FY2021 · AI · contact PI

Rationally Designed Pan-Ebolavirus Vaccine$1,240,735

R01 · FY2020 · AI · contact PI

Evolution of anti-filovirus B cell responses and mechanisms of protection$738,574

R01 · FY2020 · AI · contact PI

Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein$300,000

R41 · FY2020 · AI · contact PI

Rationally Designed Pan-Ebolavirus Vaccine$1,246,581

R01 · FY2019 · AI · contact PI

Multivalent Toxoid Vaccine for Prevention of S. aureus Invasive Diseases$761,776

R01 · FY2019 · AI · contact PI

Evolution of anti-filovirus B cell responses and mechanisms of protection$742,509

R01 · FY2019 · AI · contact PI

Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein$300,000

R41 · FY2019 · AI · contact PI

Remodeled glycoprotein for broad protection against ebolaviruses$299,186

R43 · FY2019 · AI · contact PI

Rationally Designed Pan-Ebolavirus Vaccine$1,372,407

R01 · FY2018 · AI · contact PI

Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease$1,000,000

R42 · FY2018 · AI · contact PI

Multivalent Toxoid Vaccine for Prevention of S. aureus Invasive Diseases$775,672

R01 · FY2018 · AI · contact PI

Evolution of anti-filovirus B cell responses and mechanisms of protection$750,143

R01 · FY2018 · AI · contact PI

Remodeled glycoprotein for broad protection against ebolaviruses$302,469

R43 · FY2018 · AI · contact PI

Serotype independent therapeutic vaccine for Streptococcus pneumoniae$191,255

R43 · FY2018 · AI · contact PI

Rationally Designed Pan-Ebolavirus Vaccine$1,691,927

R01 · FY2017 · AI · contact PI

Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease$861,259

R42 · FY2017 · AI · contact PI

Multivalent Toxoid Vaccine for Prevention of S. aureus Invasive Diseases$758,111

R01 · FY2017 · AI · contact PI

Evolution of anti-filovirus B cell responses and mechanisms of protection$754,197

R01 · FY2017 · AI · contact PI

Serotype independent therapeutic vaccine for Streptococcus pneumoniae$247,510

R43 · FY2017 · AI · contact PI

Multivalent Toxoid Vaccine for Prevention of S. aureus Invasive Diseases$779,398

R01 · FY2016 · AI · contact PI

Structure-guided redesign of monoclonal antibodies targeting conserved filovirus epitopes$284,365

R43 · FY2016 · AI · contact PI

Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease$229,991

R41 · FY2016 · AI · contact PI

Multivalent Toxoid Vaccine for Prevention of S. aureus Invasive Diseases$411,925

R01 · FY2015 · AI · contact PI

Infection Site Targeted Antitoxin Antibody (ISTAb) against Clostridium difficile$230,063

R43 · FY2015 · AI · contact PI

Multivalent Toxoid Vaccine for Prevention of S. aureus Invasive Diseases$646,748

R56 · FY2014 · AI · contact PI

Multi-specific Antibody Therapy by targeting S. aureus toxins and polysaccharides$293,316

R43 · FY2013 · AI · contact PI

Therapeutic Human Monoclonal Antibodies Against Staphylococcal Enterotoxin B (SEB$1,200,242

U01 · FY2012 · AI · contact PI

Multi-specific Antibody Therapy by targeting S. aureus toxins and polysaccharides$300,000

R43 · FY2012 · AI · contact PI

Therapeutic Human Monoclonal Antibodies Against Staphylococcal Enterotoxin B (SEB$1,214,480

U01 · FY2011 · AI · contact PI

Development of a Panton Valentine Leukocidin bivalent vaccine$300,000

R43 · FY2011 · AI · contact PI

Therapeutic Human Monoclonal Antibodies Against Staphylococcal Enterotoxin B (SEB$1,217,384

U01 · FY2010 · AI · contact PI

Development of a Panton Valentine Leukocidin bivalent vaccine$300,000

R43 · FY2010 · AI · contact PI

Therapeutic Human Monoclonal Antibodies Against Staphylococcal Enterotoxin B (SEB$1,031,598

U01 · FY2009 · AI · contact PI

Therapeutic Human Monoclonal Antibodies Against Staphylococcal Enterotoxin B (SEB$719,179

U01 · FY2008 · AI · contact PI

TRACKING OF EBOLA VIRUS ASSEMBLY IN LIVE CELLS$540

P41 · FY2005 · RR

TRACKING OF E BOLA VIRUS ASSEMBLY IN LIVE CELLS$17,996

P41 · FY2004 · RR